Home > Press > Nanogen Reaches Milestone in CDC Influenza Project
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has delivered the second phase milestone requirements, including the point-of-care prototype device to detect influenza viruses rapidly in clinical samples, to the Center for Disease Control and Prevention (CDC) for their evaluation. Nanogen, together with business partner HX Diagnostics, had been awarded a contract from the CDC to fund an accelerated multiphase development plan for a rapid diagnostic test for pandemic flu. Delivery of the prototype device is an important milestone demonstrating the feasibility of meeting the CDC's specifications for the rapid test. The company is continuing product development and initiating clinical trials with further funding of the project pending approval by the CDC.
Nanogen Reaches Milestone in CDC Influenza Project
SAN DIEGO, CA | Posted on December 10th, 2007
"We're very excited with the progress we have made on this project" stated Howard Birndorf, CEO of Nanogen. "Meeting the CDC requirements to develop a rapid but highly sensitive diagnostic test that would identify multiple influenza strains has been challenging. We're proud of the innovative development work done by our team and pleased to bring our expertise in advanced diagnostic technologies and infectious diseases to bear on this important global healthcare problem."
Each year 5%-20% of the U.S. population is affected by the influenza virus with approximately 36,000 deaths each year caused by the infection. Healthcare agencies, like the CDC, are concerned about the possibility of a deadly subtype, like avian flu, rapidly emerging and causing a pandemic. Tests like the one being developed by Nanogen under this contract will not only help healthcare providers to reliably diagnose the influenza virus but, also will be able to act as a sentinel for a potential outbreak of a pandemic H5 strain.
About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and kits based on the Companyís proprietary probe technology branded as MGB Alertģ and Q-PCR Alert, and a line of rapid point-of-care diagnostic tests used in urgent care settings to aid in the diagnosis of heart failure conditions. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogenís website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Robert Saltmarshm, Chief Financial Officer, 858-410-4600
Kelly Gann, Marketing Communications, 858-410-4667
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nano Labs Shareholder Update March 8th, 2014
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Nano Labs Shareholder Update March 8th, 2014
Squeezing light into metals: University of Utah engineers control conductivity with inkjet printer March 7th, 2014
Up-Converted Radio: The way to treat radio waves in a noisy environment is to turn them into visible light March 7th, 2014
Carbodeon NanoDiamonds PTFE Coating doubles surface durability and reduces friction by up to 66 percent: New surface coating enables cost-effective CO2 and fuel reductions in machinery March 6th, 2014